| __timestamp | Axsome Therapeutics, Inc. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1392830 | 504755000 |
| Thursday, January 1, 2015 | 2419289 | 838526000 |
| Friday, January 1, 2016 | 6343648 | 1177697000 |
| Sunday, January 1, 2017 | 7206691 | 1320433000 |
| Monday, January 1, 2018 | 9351522 | 1556200000 |
| Tuesday, January 1, 2019 | 13598030 | 1834800000 |
| Wednesday, January 1, 2020 | 28896749 | 1346000000 |
| Friday, January 1, 2021 | 66646205 | 1824900000 |
| Saturday, January 1, 2022 | 159253661 | 2115900000 |
| Sunday, January 1, 2023 | 323123000 | 2631300000 |
| Monday, January 1, 2024 | 411359000 | 2954400000 |
Unleashing insights
In the competitive world of biotechnology, understanding the financial strategies of industry leaders is crucial. Over the past decade, Regeneron Pharmaceuticals, Inc. and Axsome Therapeutics, Inc. have showcased contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Regeneron's SG&A expenses have consistently grown, peaking at approximately $2.63 billion in 2023, reflecting a strategic investment in operational expansion and market penetration. In contrast, Axsome Therapeutics, starting with a modest $1.4 million in 2014, has seen a staggering increase of over 23,000%, reaching $323 million in 2023. This dramatic rise underscores Axsome's aggressive growth strategy and its commitment to scaling operations. These trends highlight the dynamic nature of the biotech sector, where financial agility and strategic foresight are key to sustaining competitive advantage.
Selling, General, and Administrative Costs: AstraZeneca PLC vs Axsome Therapeutics, Inc.
Pfizer Inc. or Regeneron Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Regeneron Pharmaceuticals, Inc. or Viatris Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Exelixis, Inc.
Breaking Down SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Apellis Pharmaceuticals, Inc.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs MorphoSys AG Trends and Insights
Regeneron Pharmaceuticals, Inc. or Ligand Pharmaceuticals Incorporated: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Novavax, Inc.
GSK plc vs Axsome Therapeutics, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Axsome Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Catalent, Inc. or Axsome Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Opthea Limited and Axsome Therapeutics, Inc.